Hindustan Laboratories Receives Observations from Securities and Exchange Board of India on Proposed Initial Public Offering

Hindustan Laboratories Limited Receives SEBI Observations for Proposed IPO

Hindustan Laboratories Limited, a leading Indian pharmaceutical company, has received observations from the Securities and Exchange Board of India (SEBI) for its proposed initial public offering (IPO). The company plans to raise funds through the IPO, which will comprise a fresh issue of up to 50,00,000 equity shares and an offer for sale (OFS) of up to 91,00,000 equity shares.

Key Details of the IPO

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

The offer, with a total issue size of up to 1,41,00,000 equity shares, is expected to be a significant milestone for the company. The net proceeds from the IPO will be utilized to fund the company's working capital requirements and general corporate purposes.

Promoter's Share Sale

Rajesh Vasantray Doshi, the promoter selling shareholder, will offload up to 91,00,000 shares under the OFS component of the IPO. This move is expected to provide liquidity to the promoter and also mark a significant step towards the company's transition to a publicly listed entity.

Listing Details

Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO

The company proposes to list its shares on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). The listing is expected to provide an opportunity for investors to participate in the growth story of Hindustan Laboratories Limited.

Business Overview

Hindustan Laboratories Limited is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework. The company's products are primarily generic formulations, which are medicines whose patents have expired and are typically used as substitutes for more expensive branded medicines.

Supply Chain and Distribution

The company supplies its products mainly under procurement contracts for central government projects under the Ministry of Health and Family Welfare through Government of India agencies, as well as through various state government agencies and bodies. During the six months ended September 30, 2025, the company supplied its products across India to 27 states and Union Territories, and during Fiscal 2025, it supplied products to 27 states and Union Territories, as per the draft red herring prospectus (DRHP).

Product Portfolio

The company's products are supplied either under brand names or under their generic names, depending on the specific requirements and preferences of its customers. Regardless of the nomenclature, all the company's products (save for those manufactured for others) carry its logo, ensuring consistent brand identity and quality assurance.